Heterogeneity in the composition of marijuana seized in California

Drug and Alcohol Dependence

Volumn 117, Issue 1, 2011, Pages 59-61

  Burgdorf, James Richard ^a   Kilmer, Beau ^a   Pacula, Rosalie Liccardo ^a  

^a RAND CORPORATION   (United States)

Author keywords

California; Cannabidiol; Marijuana; Mental health; Potency; Tetrahydrocannabinol

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL;

ARTICLE; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; LAW ENFORCEMENT; PRIORITY JOURNAL; RECREATION; UNITED STATES;

CALIFORNIA; CANNABIDIOL; CANNABIS; DATABASES, FACTUAL; HUMANS; LAW ENFORCEMENT; PSYCHOTROPIC DRUGS; TETRAHYDROCANNABINOL;

CANNABIS SATIVA;

EID: 79959684881     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.11.031     Document Type: Article

References (22)

1. Crippa, J.A.S., Derenusson, G.N., Ferrari, T.B., Wichert-Ana, L., Duran, F., Marti-n-Santos, R., Simões, M.V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Filho, A.S., Freitas-Ferrari, M.C., McGuire, P., Zuardi, A.W., Busatto, G., Hallak, J.E.C., 2010. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. [Epub ahead of print]. Available from: accessed on October 19, 2010. http://jop.sagepub.com/content/early/2010/09/08/0269881110379283.
2. Crippa J.A., Zuardi A.W., Martín-Santos R., Bhattacharyya S., Atakan Z., McGuire P., Fusar-Poli P. Cannabis and anxiety: a critical review of the evidence. Hum. Psychopharmacol. 2009, 24:515-523.
3. Di Forti M., Morgan C., Dazzan P., Pariante C., Mondelli V., Marques T.R., Handley R., Luzi S., Russo M., Paparelli A., Butt A., Stilo S.A., Wiffen B., Powell J., Murray R.M. High-potency cannabis and the risk of psychosis. Br. J. Psychiatry 2009, 195:488-491.
4. Fusar-Poli P., Crippa J.A., Bhattacharyya S., Borgwardt S.J., Allen P., Martin-Santos R., Seal M., Surguldadze S.A., O'Carrol C., Atakan Z., Zuardi A.W., McGuire P.K. Distinct effects of D9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Ann. Gen. Psychiatry 2009, 66:95-105.
5. Hall W., Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009, 374:1383-1391.
6. Hall W., Pacula R.L. Cannabis Use and Dependence: Public Health and Public Policy 2003, Cambridge University Press, Melbourne.
7. Hardwick S., King L. Home Office Cannabis Potency Study 2008 2008, Home Office Scientific Development Branch, London.
8. Iversen L. The Science of Marijuana 2007, Oxford University Press, Oxford.
9. Karniol I.G., Shirakawa I., Kasinski N., Pfeferman A., Carlini E.A. Cannabidiol interferes with the effects of Δ9-tetrahydrocannabidinol in man. Eur. J. Pharmacol. 1974, 28:172-177.
10. Kilmer, B., Caulkins, J.P., Bond, B.M., Reuter, P.H., 2010. Reducing drug trafficking revenues and violence in Mexico: would legalizing marijuana in California help? RAND Publication No. OP-325-RC. RAND Corporation, Santa Monica.
11. Leweke F., Koethe D., Gerth C., Nolden B.M., Schreiber D., Gross S., Schultze-Lutter F., Hellmich M., Klosterkotter J. Cannabidiol as an antipsychotic agent. Eur. Psychiatry 2007, 22:S1-S82.
12. Mehmedic Z., Chandra S., Slade D., Denham H., Foster S., Patel A.S., Ross S.A., Khan I.A., ElSohly M.A. Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J. Forensic Sci. 2010, 55:1209-1217.
13. Morgan C.J.A., Curran H.V. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br. J. Psychiatry 2008, 192:306-307.
14. Musty R.E. Cannabinoids and anxiety. Cannabinoids as Therapeutics 2005, 141-147. Birkhäuser Verlag, Basel. R. Mechoulam (Ed.).
15. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br. J. Pharmacol. 2008, 153:199-215.
16. Potter D.J., Clark P., Brown M.B. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J. Forensic Sci. 2008, 53:90-94.
17. Room R., Fischer B., Hall W., Lenton S., Reuter P. Cannabis Policy: Moving Beyond Stalemate 2010, Oxford University Press, Oxford.
18. Sewell R.A., Ranganathan M., D'Souza D.C. Cannabinoids and psychosis. Int. Rev. Psychiatry 2009, 21:152-162.
19. Smith N. High potency cannabis: the forgotten variable. Addiction 2005, 100:1558-1559.
20. Zuardi A.W., Crippa J., Hallak J., Moreira F., Guimaraes F. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med Biol. Res. 2006, 39:421-429.
21. Zuardi A.W., Morais S., Guimaraes F., Mechoulam R. Antipsychotic effect of cannabidiol. J. Clin. Psychiatry 1995, 56:485-486.
22. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982, 76:245-252.